SCHEMBL7049219

SCHEMBL7049219

CCCCCSc1ncccn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.53
NPC1 O15118 6/20 0.53
RAB9A P51151 6/20 0.53
MAPT P10636 5/20 0.53
MAPK1 P28482 3/20 0.53
HPGD P15428 2/20 0.53
ALDH1A1 P00352 3/20 0.51
HSD17B10 Q99714 2/20 0.51
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
RECQL P46063 1/20 0.49
HTT P42858 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
LMNA P02545 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11334284 0.98 SMN1; SMN2 (0.51) SMN1; SMN2NPC1RAB9AMAPTMAPK1
SCHEMBL423622 0.93 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9AMAPTMAPK1
SCHEMBL9435490 0.93 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9AMAPTMAPK1
SCHEMBL4325251 0.89 ALDH1A1 (0.58) SMN1; SMN2NPC1RAB9AMAPTMAPK1
SCHEMBL9956852 0.84 NPC1 (0.58) SMN1; SMN2NPC1RAB9AMAPTMAPK1
SCHEMBL7055583 0.81 PAK1 (0.44) SMN1; SMN2NPC1RAB9AMAPTMAPK1
SCHEMBL29731549 0.79 SMN1; SMN2 (0.45) SMN1; SMN2NPC1RAB9AMAPTMAPK1
SCHEMBL11821001 0.79 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9AMAPTMAPK1
SCHEMBL3691473 0.79 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9AMAPTMAPK1
SCHEMBL5586189 0.79 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9AMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101257948-A Pyrimidine-fused diazepine derivatives and indole-fused pteridines ATTENUON LLC (US) 2008-09-03 CN disclosed
US-6818648-B2 PSYCHOLOGICAL DISORDERS; ANXIOLYTIC AGENTS; ANTIDEPRESSANTS; EATING DISORDERS; ALCOHOLISM; DRUG ABUSE; ANTIINFLAMMATORY AGENTS BRISTOL-MYERS SQUIBB PHARMA 2004-11-16 US disclosed
US-20030191125-A1 Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-10-09 US disclosed
US-20020040026-A1 Aryloxy-and arylthiosubstituted pyrimidines and triazines and derivatives thereof DUPONT PHARMACEUTICALS COMPANY 2002-04-04 US disclosed
US-6326368-B1 PSYCHOLOGICAL DISORDERS DUPONT PHARMACEUTICALS COMPANY 2001-12-04 US disclosed
EP-0920318-A4 ARYLOXY- AND ARYLTHIOSUBSTITUTED PYRIMIDINES AND TRIAZINES AND DERIVATIVES THEREOF DU PONT PHARM CO (US) 2000-03-15 EP disclosed
EP-0920318-A1 ARYLOXY- AND ARYLTHIOSUBSTITUTED PYRIMIDINES AND TRIAZINES AND DERIVATIVES THEREOF Du Pont Pharmaceuticals Company (US) 1999-06-09 EP disclosed
WO-1997035580-A1 ARYLOXY- AND ARYLTHIOSUBSTITUTED PYRIMIDINES AND TRIAZINES AND DERIVATIVES THEREOF DU PONT PHARMACEUTICALS COMPANY (US) 1997-10-02 WO disclosed
US-5426090-A Herbicides SHELL RESEARCH LIMITED (GB) 1995-06-20 US disclosed
EP-0431707-A2 Heterocyclic compounds SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1991-06-12 EP disclosed
US-4888047-A FOR ANNUAL AND PERENNIAL GRASSES AND BROADLEAF WEEDS; POSTEMERGENCE ICI AMERICAS INC. (US) 1989-12-19 US disclosed
US-4888047-A FOR ANNUAL AND PERENNIAL GRASSES AND BROADLEAF WEEDS; POSTEMERGENCE ICI AMERICAS INC. (US) 1989-12-19 US disclosed
EP-0219835-A3 ACYLAMINOARYLOXY AND ARYLTHIO PYRIMIDINES STAUFFER CHEMICAL COMPANY (US) 1988-02-10 EP disclosed
EP-0219835-A3 ACYLAMINOARYLOXY AND ARYLTHIO PYRIMIDINES STAUFFER CHEMICAL COMPANY (US) 1988-02-10 EP disclosed
EP-0219835-A2 Acylaminoaryloxy and arylthio pyrimidines STAUFFER CHEMICAL COMPANY (US) 1987-04-29 EP disclosed
EP-0219835-A2 Acylaminoaryloxy and arylthio pyrimidines STAUFFER CHEMICAL COMPANY (US) 1987-04-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191125-A1 Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof PARL, HTR5A, PSEN2 SMN1; SMN2 3243/4885NPC1 2910/4885RAB9A 2435/4885
US-20020040026-A1 Aryloxy-and arylthiosubstituted pyrimidines and triazines and derivatives thereof PARL, HTR5A, PSEN2 SMN1; SMN2 3224/4885NPC1 2930/4885RAB9A 2452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.